Journal
FRONTIERS IN ONCOLOGY
Volume 10, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2020.611690
Keywords
rapamycin; Rapalogs; mTOR pathway; malignant and benign hemopathies; graft-versus-host disease
Categories
Funding
- Science and Technology Innovation Capacity Promotion Project of Army Medical University [2019XLC3014]
- Natural Science Foundation of Chongqing [cstc2019jcyj-msxmX0273, cstc2020jcyjmsxmX1086]
- Special Projects in the Frontier of Military Medicine Natural Science of Xinqiao Hospital [2018 YQYLY002]
- National Key Research Program [2017YF A0105502]
Ask authors/readers for more resources
mTOR inhibitors, such as Rapamycin and Rapamycin analogs, have emerged as a promising class of agents for treating malignant blood diseases. Their evolving role in the management of hematologic disease, including leukemia, lymphoma, myeloma, immune hemocytopenia, and GVHD, is supported by experimental evidence of their molecular mechanisms. These inhibitors are increasingly seen as a trusted therapeutic in the clinical hematologist's toolbelt and should be considered more routinely in combination therapy.
The mTOR pathway plays a central role in many cellular processes, such as cellular growth, protein synthesis, glucose, and lipid metabolism. Aberrant regulation of mTOR is a hallmark of many cancers, including hematological malignancies. mTOR inhibitors, such as Rapamycin and Rapamycin analogs (Rapalogs), have become a promising class of agents to treat malignant blood diseases-either alone or in combination with other treatment regimens. This review highlights experimental evidence underlying the molecular mechanisms of mTOR inhibitors and summarizes their evolving role in the treatment of hematologic disease, including leukemia, lymphoma, myeloma, immune hemocytopenia, and graft-versus-host disease (GVHD). Based on data presented in this review, we believe that mTOR inhibitors are becoming a trusted therapeutic in the clinical hematologist's toolbelt and should be considered more routinely in combination therapy for the management of hematologic disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available